

The Manager
Company Announcements Office
ASX Limited

LBT RECEIVES NOTICE OF ALLOWANCE FOR SECOND PATENT COVERING CORE APAS TECHNOLOGY IN UNITED STATES

Adelaide, 14 October 2015: Australian medical technology company LBT Innovations Limited (ASX: LBT) has received a Notice of Allowance from the US Patent & Trademark Office for a second US patent protecting the core software underpinning its pioneering culture-plate analysis technology, the Automated Plate Assessment System (APAS®).

The Notice of Allowance relates to US patent application no. 14/002,722, which covers the key systems and software for analysing and assessing microbial growth by APAS, which is due to be the subject of a 510(k) *de novo* submission to the US Food & Drug Administration (FDA) later this year.

When issued, the patent will provide intellectual property protection for APAS software until at least March 2032. The prospects of APAS were significantly bolstered last week with the announcement of successful results from a pivotal clinical trial at TriCore Reference Laboratories in the US, which showed APAS achieving over 98% sensitivity in its detection of disease-causing bacteria in urine samples from 5,500 patients.

The latest allowed patent application is part of a patent portfolio of four related inventions covering the APAS technology, for which LBT initiated patent protection early in 2011. The first US patent, granted in March this year, related to a novel method for 'colour calibrating' images captured by APAS.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: MicroStreak®, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture with Hettich AG Switzerland to drive the commercialisation of APAS products. LBT also has a third product in development, WoundVue™, a proposed automation solution to assist in the management of chronic wounds.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie, CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson, Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au